Aflibercept/Nesvacumab

N/A

Report date: 2025/08/01 14:25:37

Base Information

Drug NameAflibercept/Nesvacumab
Drug Alias NameNesvacumab/EyleaAng2 antibody/EyleaEylea/Ang2-antibodyAflibercept+NesvacumabNesvacumab+Aflibercept +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitorsAngiopoietin-2 inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor AAngiopoietin-2
Therapy Area/IndicationsDiabetic macular oedemaMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes AfliberceptNesvacumab
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegeneron Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsDiabetic macular oedemaMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A